GlassScriptPhysician profile
Candace M Marr
NPI 1922341775
$1,148.77
in general payments reported to CMS, 2019-2025
15 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.30 · 2022: $154 · 2023: $392 · 2024: $282 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.14 |
| Education | $247.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $241.60 | 2023-2025 | Cresemba |
| Insmed, INC. | $214.69 | 2022-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $142.61 | 2022-2025 | Zerbaxa, Dificid, Pifeltro |
| Shionogi INC | $91.83 | 2022-2024 | Fetroja |
| Solventum Corporation | $71.29 | 2025 | Activ.A.C. |
| Janssen Biotech, INC. | $66.24 | 2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $65.93 | 2022-2025 | Nuzyra |
| Smith+Nephew, INC. | $45.41 | 2022 | |
| Abbvie INC. | $44.75 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $43.27 | 2024 | |
| Ferring Pharmaceuticals INC. | $34.61 | 2023 | Rebyota |
| Gilead Sciences, INC. | $25.68 | 2025 | |
| Tactile Systems Technology INC | $25.44 | 2024 | Entre Plus, Flexitouch Plus |
| Viiv Healthcare Company | $23.47 | 2024 | Cabenuva |
| Melinta Therapeutics, LLC | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Marr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.